Think of biotech and the bioeconomy as a broad methodology encompassing all those who use and borrow from biology to produce ...

A St. Louis-based clinical-stage biotechnology company developing cancer-fighting drugs has hired a new medical chief. Wugen ...

KBW Ventures founder and CEO HRH Prince Khaled bin Alwaleed bin Talal Al Saud announced new KBW Ventures' investments in ...

Researchers at ETH Zurich combined two CRISPR-Cas methods to decipher how mutations in a cell’s genome affect its function.

About a year after cutting staff by 29%, Sana Biotechnology will trim its workforce as it increases investment in its type 1 ...

In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...

VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

Together, they advance our understanding of biological processes, paving the way for innovations in healthcare, biotechnology ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

In the rapidly advancing field of biotechnology, precise analysis and accurate measurement are critical for research and ...

As one of the premier global events for the biotechnology, pharmaceutical, and investment sectors, over 5,500 attendees join, representing more than 2,800 companies and over 60 countries. At the event ...

Sana Biotechnology Inc.的股价已跌至52周新低，触及2.75美元。该公司正在生物科技板块的艰难时期中前行，过去一年股价大幅回落，跌幅达20.4%。投资者正密切关注Sana在这个关键价格水平的战略举措，希望能出现转机，可能重振对该股未来表现的信心。 在其他近期新闻中，Sana Biotechnology宣布了其管线的战略调整，将重点放在1型糖尿病和B细胞驱动的自身免疫疾病上。公 ...